Vertex Pharmaceuticals Incorporated (VRTX) Financials

VRTX Assets vs Liabilities

DateAssetsLiabilities
March 31, 2026 26.5 billion 7.1 billion
Dec. 31, 2025 26.1 billion 7.5 billion
Sept. 30, 2025 24.9 billion 7.5 billion
June 30, 2025 24.0 billion 6.9 billion

VRTX Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 1.3 billion 166.4 million
Dec. 31, 2025 348.6 million 157.6 million
Sept. 30, 2025 1.1 billion 194.9 million
June 30, 2025 927.4 million 167.3 million

VRTX Net Income

Graph available only for paid members. Upgrade to see it.
DateNet Income
March 31, 2026 1.0 billion
Dec. 31, 2025 1.2 billion
Sept. 30, 2025 1.1 billion
June 30, 2025 1.0 billion

VRTX Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 7.2 billion - 2.0 billion
Dec. 31, 2025 6.6 billion 1.8 billion 2.0 billion
Sept. 30, 2025 6.3 billion - 1.8 billion
June 30, 2025 6.4 billion - 1.5 billion

VRTX Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 256.3 million
Dec. 31, 2025 256.1 million
Sept. 30, 2025 257.6 million
June 30, 2025 258.9 million

VRTX Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 133.4 million 961.6 million 493.7 million -
Dec. 31, 2025 149.4 million 973.7 million 487.0 million -
Sept. 30, 2025 101.8 million 1.0 billion 445.1 million -
June 30, 2025 145.7 million 978.4 million 424.6 million -

VRTX Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 3.0 billion 392.8 million
Dec. 31, 2025 3.2 billion 466.0 million
Sept. 30, 2025 3.1 billion 414.8 million
June 30, 2025 3.0 billion 407.5 million

VRTX Revenue by Segment

Graph available only for paid members. Upgrade to see it.

VRTX

Price: $446.83

52 week price:
362.50
507.92

Payout Ratio Range:
0.37%
24.93%

Earnings Per Share: 16.85 USD

P/E Ratio: 25.51

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 1.1 million

Ebitda: 142.2 million

Market Capitalization: 108.7 billion

Links: